CAMP4 Therapeutics Prepares CMP-002 Phase 1/2 Trial for SYNGAP1
WATERTOWN, Mass. — September 8, 2026 CAMP4 Therapeutics Corporation announced plans to host a virtual Analyst Day on September...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
WATERTOWN, Mass. — September 8, 2026 CAMP4 Therapeutics Corporation announced plans to host a virtual Analyst Day on September...
Hong Kong, August 14, 2026 Insilico Medicine, a clinical-stage drug discovery company powered by generative artificial intelligence (AI), has...
Houston, Texas, August 14, 2026 Fannin Partners, LLC has received new grants from the Congressionally Directed Medical Research Programs...
Seoul, South Korea, August 12, 2026 THPharm is advancing an artificial intelligence-driven indication expansion strategy in partnership with Insilico...
NEEDHAM, Mass., Aug. 3, 2026 Candel Therapeutics, Inc. announced that new data from its Phase 3 clinical program evaluating...
CARLSBAD, Calif., Aug. 3, 2026 Design Therapeutics, Inc. reported second-quarter 2026 financial results while providing key clinical updates across...
DURHAM, N.C., July 8, 2026 GeneCentric has announced the launch of ExpressCT Rewind™, a retrospective fragmentomics analysis service designed...
TARPON SPRINGS, Fla., June 30, 2026 Allarity Therapeutics, Inc. announced that the U.S. Patent and Trademark Office (USPTO) has...
